CellMP

Executive Summary

CellMP is a US-based contract development and manufacturing organization (CDMO) specializing in cell therapies, founded in 2020 and headquartered in Cambridge, Massachusetts. The company offers process development, scale-up, and GMP manufacturing services for investigational cell therapy products, supporting clients from pre-clinical research through early-stage clinical trials. Additionally, CellMP provides R&D consulting and technology transfer to bridge the gap between research and clinical application. Operating as a private, pre-clinical stage company, CellMP focuses on enabling cell therapy developers to accelerate their programs by offering flexible, high-quality manufacturing solutions. CellMP addresses the growing demand for specialized cell therapy manufacturing capacity, particularly as the cell therapy market expands. Its services cater to both academic and biotech clients seeking to outsource complex manufacturing processes. Despite being a relatively early-stage player, CellMP differentiates through its technical expertise, agile project management, and proximity to major biotech hubs. The company faces competition from larger CDMOs but can capture niche opportunities in process development and early-phase production. Key upcoming catalysts include client contract wins, expansion of manufacturing capabilities, and strategic partnerships to secure long-term capacity commitments.

Upcoming Catalysts (preview)

• Q3 2026New Client Contract for GMP Manufacturing65% success
• Q4 2026Completion of Facility Expansion or New Suite50% success
• Q3 2026Strategic Partnership with Cell Therapy Developer40% success